Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease. Source
No articles found.
HealthEquity provides a solution to an issue of growing importance to American fam...
HealthEquity provides a solution to an issue of...
We are a leading science and technology company that delivers life-transforming me...
We are a leading science and technology company...
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a no...
Bicycle Therapeutics is a clinical-stage biopha...
Lexicon Pharmaceuticals is a fully integrated biopharmaceutical company that is ap...
Lexicon Pharmaceuticals is a fully integrated b...
Syneos HealthÂŽ (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solut...
Syneos HealthÂŽ (Nasdaq:SYNH) is the only fully...
Hutchison China MediTech Limited, known as Chi-Med, is an innovative biopharmaceut...
Hutchison China MediTech Limited, known as Chi-...
VBI Vaccines Inc. (Nasdaq: VBIV) is a commercial-stage biopharmaceutical company d...
VBI Vaccines Inc. (Nasdaq: VBIV) is a commercia...
Join the National Investor Network and get the latest information with your interests in mind.